Company intelligence / Profile preview

Wild Microbes

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

Wild Microbes is an active private biotech company specializing in synthetic biology-driven discovery and engineering of novel wild microbial species as next-generation hosts for sustainable biomanufacturing. Their proprietary high-throughput genetic toolkit enables rapid domestication and optimization of these unique microbes primarily aimed at producing proteins used across food ingredients, cosmetics and cleaning industries with future expansion into specialty chemicals. Founded by Tim Wannier and Ben Kramer, they recently closed a $3.3M pre-seed financing led by Climate Capital Bio, among others.

Therapeutic areas: Other
Modalities: Microbial engineeringSynthetic biology
Industry: Non-Drug Biotech

Partnerships

Innovative partners in industry (names not publicly disclosed)

Beyond the preview

Go deeper on Wild Microbes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wild Microbes.

Explore the full profile